...
首页> 外文期刊>Investigative ophthalmology & visual science >Effects of adenosine on intraocular pressure, optic nerve head blood flow, and choroidal blood flow in healthy humans.
【24h】

Effects of adenosine on intraocular pressure, optic nerve head blood flow, and choroidal blood flow in healthy humans.

机译:腺苷对健康人的眼压,视神经乳头血流和脉络膜血流的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE. There is evidence from a variety of animal studies that the adenosine system plays a role in the control of intraocular pressure (IOP) and ocular blood flow. However, human data on the effect of adenosine on IOP and choroidal and optic nerve blood flow are not available. METHODS. The effect of stepwise increases in doses of adenosine (10, 20, and 40 micro g/kg per minute, 30 minutes per infusion step) on optic nerve head blood flow, choroidal blood flow, and IOP was determined in a placebo-controlled double-masked clinical trial in 12 healthy male volunteers. Blood flow in the optic nerve head and choroid was measured with laser Doppler flowmetry. In addition, fundus pulsation amplitude in the macula (FPAM) and the optic nerve head (FPAO) were assessed with laser interferometry. RESULTS. Adenosine induced a small but significant decrease in IOP (at 40 micro g/kg per minute: 12% +/- 13%), which was significant versus placebo (P = 0.046). In addition, adenosine induced a significant increase in choroidal blood flow (P < 0.001) and optic nerve head blood flow (P = 0.037), and FPAM (P = 0.0014) and tended to increase FPAO (P = 0.057). At the highest administered dose, the effect on choroidal hemodynamic parameters between 14% and 17%, whereas the effect on optic nerve hemodynamic parameters was between 3% and 11%. CONCLUSIONS. These data are consistent with adenosine inducing choroidal and optic nerve head vasodilatation and reducing IOP in healthy humans. Considering the neuroprotective properties of adenosine described in previous animal experiments the adenosine system is an attractive target system for therapeutic approaches in glaucoma.
机译:目的。来自各种动物研究的证据表明,腺苷系统在控制眼内压(IOP)和眼血流量中起作用。但是,尚无有关腺苷对IOP以及脉络膜和视神经血流影响的人类数据。方法。在安慰剂对照双控下确定腺苷剂量逐步增加(每分钟10、20和40微克/千克,每次输注30分钟)对视神经头部血流,脉络膜血流和IOP的影响一项针对12名健康男性志愿者的掩盖临床试验。用激光多普勒血流仪测量视神经头和脉络膜中的血流。此外,用激光干涉仪评估了黄斑(FPAM)和视神经头(FPAO)的眼底搏动幅度。结果。腺苷引起眼压的轻微但显着降低(以40微克/千克每分钟的速度:12%+/- 13%),与安慰剂相比是显着的(P = 0.046)。此外,腺苷引起脉络膜血流(P <0.001)和视神经头血流(P = 0.037)和FPAM(P = 0.0014)显着增加,并倾向于增加FPAO(P = 0.057)。在最高给药剂量下,对脉络膜血流动力学参数的影响在14%至17%之间,而对视神经血流动力学参数的影响在3%至11%之间。结论。这些数据与腺苷诱导健康人的脉络膜和视神经头血管舒张并降低IOP一致。考虑到先前动物实验中描述的腺苷的神经保护特性,腺苷系统是青光眼治疗方法中有吸引力的靶标系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号